Ascendis Pharma A (ASND) Notes Payables (2021 - 2026)

Ascendis Pharma A has disclosed Notes Payables across 6 years of filings, most recently posting $524.7 million for Q1 2026.

• Notes Payables for Q1 2026 came in at $524.7 million, up 10.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $524.7 million (up 10.96% YoY), and the FY2025 annual result was $499.8 million, up 2.08% from the prior year.
• Notes Payables came in at $524.7 million for Q1 2026 at Ascendis Pharma A, up from $499.8 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $598.2 million in Q3 2023 to a low of $395.4 million in Q4 2022.
• The 5-year median for Notes Payables is $498.3 million (2025), against an average of $494.6 million.
• Across the five-year window, Notes Payables jumped 252.82% in 2022 and dropped 22.51% in 2024, its largest moves.
• Ascendis Pharma A's Notes Payables stood at $395.4 million in 2022, then advanced by 10.78% to $438.0 million in 2023, then climbed by 11.79% to $489.6 million in 2024, then gained by 2.08% to $499.8 million in 2025, then grew by 4.98% to $524.7 million in 2026.
• The last three Notes Payables figures came in at $524.7 million (Q1 2026), $499.8 million (Q4 2025), and $498.3 million (Q3 2025), per Business Quant data.